Allergy and Immunology, Allergy · El Paso, TX
NPI
1447254784
Since 2005
Specialty
Allergy and Immunology, Allergy
Code 207KA0200X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
11410 Vista del Sol Dr
El Paso, TX, 79936
Phone (915) 592-6269
Groups this clinician bills Medicare through
Medicare paid, 2024
$398K
13,960 services
Medicare patients, 2024
277
Average age 73
Drug cost, 2024
$4.8M
2,377 prescriptions
Company payments, 2025
$2,052
From 18 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Jose Venzor III was code J2357 (injection, omalizumab, 5 mg), 4,831 times for 11 patients. In total Jose Venzor III billed 13,960 services in 32 codes, and Medicare paid $398K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-08-11.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J2357 Injection, omalizumab, 5 mg | Office | 4,831 | 11 | $29.75 | $144K |
| 95004 Test - Miscellaneous | Office | 3,385 | 55 | $2.67 | $9,045 |
| 95117 Treatment - Miscellaneous | Office | 672 | 56 | $7.87 | $5,288 |
| 95165 Treatment - Miscellaneous | Office | 605 | 66 | $8.85 | $5,354 |
| 95115 Treatment - Miscellaneous | Office | 360 | 29 | $6.95 | $2,501 |
| 99214 Office E&M - Established | Office | 350 | 196 | $84.50 | $30K |
| 96372 Injection Administration | Office | 304 | 63 | $10.31 | $3,135 |
| J0696 Injection, ceftriaxone sodium, per 250 mg | Office | 203 | 27 | $0.33 | $67.82 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 129 | 79 | $12.47 | $1,608 |
| J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 118 | 29 | $0.74 | $86.86 |
| 99204 Office E&M - New | Office | 66 | 66 | $113.80 | $7,511 |
| 99213 Office E&M - Established | Office | 51 | 38 | $50.23 | $2,562 |
| 87804 Immunoassay | Office | 40 | 21 | $16.22 | $649 |
| 99215 Office E&M - Established | Office | 28 | 23 | $120.60 | $3,377 |
| 87426 Immunoassay | Office | 27 | 22 | $34.62 | $935 |
By year: 2022 $379K for 12,641 services; 2023 $328K for 11,373 services; 2024 $398K for 13,960 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 87804 Immunoassay | 40 | 21 | $16.22 | $649 |
| 87426 Immunoassay | 27 | 22 | $34.62 | $935 |
Medicare prescription drug claims, 2024
In 2024, the drug Jose Venzor III prescribed most often to Medicare patients was Levocetirizine Dihydrochloride, with 278 prescriptions and refills. In total Jose Venzor III wrote 2,377 Medicare prescriptions that cost $4.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levocetirizine Dihydrochloride Generic | 278 | 541 | 83 | $2,893 |
| Montelukast Sodium Generic | 242 | 591 | 81 | $3,195 |
| Desloratadine Generic | 196 | 396 | 75 | $8,192 |
| Azelastine Hcl Generic | 168 | 322 | 83 | $6,664 |
| Xolair Omalizumab | 134 | 138 | 13 | $420K |
| Fluticasone Propionate Generic | 108 | 247 | 45 | $2,277 |
| Carbinoxamine Maleate Generic | 108 | 183 | 44 | $4,978 |
| Albuterol Sulfate Hfa Albuterol Sulfate | 104 | 146 | 44 | $3,837 |
| Prednisone Generic | 78 | 82 | 55 | $153 |
| Cefuroxime Cefuroxime Axetil | 72 | 72 | 61 | $1,213 |
| Hydroxyzine Hcl Generic | 67 | 103 | 18 | $779 |
| Kalbitor Ecallantide | 47 | 47 | Under 11 | $1.5M |
| Dupixent Syringe Dupilumab | 47 | 47 | Under 11 | $210K |
| Mometasone Furoate Generic | 42 | 82 | 16 | $3,524 |
| Famotidine Generic | 38 | 62 | 13 | $332 |
Brand drugs: 503 claims; generic drugs: 1,874 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Jose Venzor III $2,052 ($2,052 in general payments such as food, travel and fees) from 18 companies. The largest payer was AstraZeneca Pharmaceuticals LP with $530.
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP AZN | 14 | $530 |
| Genzyme Corporation SNY | 15 | $284 |
| Regeneron Healthcare Solutions, Inc. REGN | 7 | $261 |
| GlaxoSmithKline, LLC. GSK | 11 | $250 |
| CSL Behring CSL.AX | 5 | $110 |
| Novartis Pharmaceuticals Corporation NVS | 5 | $110 |
| Genentech USA, Inc. ROG.SW | 4 | $105 |
| Sanofi-Aventis U.S. LLC SNY | 1 | $99.95 |
| Amgen Inc. AMGN | 2 | $57.47 |
| Incyte Corporation INCY | 2 | $46.53 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.